Articles tagged "Immunosuppression"

2019 American Transplant Congress
The Use of mTOR Inhibitors Prevents Acute Cellular Rejection in Kidney Transplantation on Belatacept Therapy
J. Shoji, J. C. Leung, Q. Tang, J. P. Roberts, F. Vincenti
University of California San Francisco, San Francisco, CA
*Purpose: Belatacept is a costimulatory blocker that is used as de novo maintenance immunosuppression in kidney transplantation to avoid toxic effects of calcineurin inhibitors and…
2019 American Transplant Congress
Conversion from Calcineurin Inhibitors to Belatacept in Kidney Recipients with Donor-Specific Anti-HLA Antibodies and Calcineurin Inhibitor Nephrotoxicity Decreases the Pathogenicity of Donor-Specific Anti-HLA Antibodies
K. Louis¹, D. Viglietti¹, D. Pievani¹, O. Aubert¹, D. Glotz¹, C. Legendre¹, A. Zeevi², A. Loupy¹, C. Lefaucheur¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France, ²University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Switching from CNI- to Belatacept-based regimen has been associated with improved graft function in low-immunologic risk kidney recipients. We investigated the efficacy and safety…
2019 American Transplant Congress
Impact of Once-Daily Tacrolimus on Trough Concentration Variability in Stable Adolescent and Young Adult Renal Transplant Recipients
M. Moss, J. Goebel, A. Lofton, E. Steinberg, M. Bock
Children's Hospital Colorado, Aurora, CO
*Purpose: High tacrolimus concentration variability (Vtac), likely influenced by medication non-adherence, is a risk factor for graft dysfunction and loss among renal transplant recipients (RTRs),…
2019 American Transplant Congress
Lack of Response to Tocilizumab in Kidney Transplants with Chronic Antibody-Mediated Rejection
D. Kumar¹, F. Safavi¹, R. Sandhu¹, P. Halloran², I. Yakubu¹, M. Levy¹, I. Moinuddin¹, P. Kimball¹, L. Kamal¹, A. King¹, H. Massey¹, G. Gupta¹
¹Virginia Commonwealth University, Richmond, VA, ²Alberta Transplant Genomics Applied Centre, Edmonton, AB, Canada
*Purpose: Chronic antibody mediated rejection (cAbMR) is a major cause of long-term kidney transplant (KT) loss. Traditional therapies for cAbMR have unclear efficacy with significant…
2019 American Transplant Congress
Early Tacrolimus Trough Attainment in De Novo Kidney Transplant Recipients Treated with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac)
K. Budde¹, S. Bunnapradist², S. J. Patel³, D. R. Stevens³, U. Meier-Kriesche³, B. Suwelack⁴
¹Charité University Medicine Berlin, Berlin, Germany, ²UCLA Medical Center, Los Angeles, CA, ³Veloxis Pharmaceuticals Inc., Cary, NC, ⁴University Hospital of Münster, Münster, Germany
*Purpose: Early achievement of therapeutic tacrolimus concentrations has been associated with reduced rates of acute rejection. A prospective, randomized, controlled study demonstrated safe and efficacious…
2019 American Transplant Congress
Difference in DSA Formation between Tacrolimus-XR and Tacrolimus-IR
J. Hagopian¹, C. Carthon¹, S. January¹, A. Gharabagi², R. Delos Santos³, T. Horwedel⁴
¹Barnes-Jewish Hospital, Saint Louis, MO, ²St. Louis College of Pharmacy, Saint Louis, MO, ³Washington University, Saint Louis, MO, ⁴Veloxis Pharmaceuticals, Inc., Cary, NC
*Purpose: Donor specific antibodies (DSA), whether pre-formed or developed de novo after kidney transplantation, have been associated with acute and chronic antibody mediated rejection, transplant…
2019 American Transplant Congress
Outcomes of Reduced Thymoglobulin Induction Dosing in Elderly Kidney Transplant Recipients at a Steroid Sparing Center
E. C. Liu, J. H. Lee, R. Abramova
Pharmacy, NewYork-Presbyterian, New York, NY
*Purpose: Studies have demonstrated a mortality benefit with kidney transplantation (KT) in elderly patients, but there is little consensus over optimal immunosuppression. Older KT recipients…
2019 American Transplant Congress
Expansion of Myeloid Derived Suppressor Cells Following Alum Administration
A. G. Cuenca, N. J. Feeney, K. Deng, C. G. Rickert, J. F. Markmann
Massachusetts General Hospital, Boston, MA
*Purpose: Immunosuppressive medications, such as calcineurin inhibitors, are critical to the survival of the transplant allograft but come with significant morbidity to the recipient and…
2019 American Transplant Congress
Performance Improvement Initiative: Ambulatory Tool to Improve Tacrolimus Intrapatient Variability (IPV) Monitoring in Kidney & Liver Transplant Recipients
T. E. Kaiser¹, N. S. Ejaz¹, S. Tremblay¹, N. J. Parrish², S. Schinasi², J. Harris², A. Govil¹, N. Anwar¹, R. R. Alloway¹
¹University of Cincinnati, Cincinnati, OH, ²UC Health, Cincinnati, OH
*Purpose: High tacrolimus (TAC) intrapatient variability (IPV) is associated with poorer outcomes. Manual monitoring of TAC IPV is labor intensive and not always feasible. As…
2019 American Transplant Congress
The Reduced Tacrolimus Metabolism Rate and Its Association with Estimated Glomerular Filtration Rate and Interstitial Fibrosis: A Study Using Korean Organ Transplantation Registry (KOTRY) Dataset
J. Jeong¹, H. Ro², T. Koo³, J. Yang³, M. Kim⁴, S. Shin⁵, J. Park⁶, T. Ban⁷, S. Han⁸, T. Kim⁹, C. Ahn¹⁰
¹Ajou University School of Medicine, Suwon, Korea, Republic of, ²Gachon University, Incheon, Korea, Republic of, ³Seoul National University Hospital, Seoul, Korea, Republic of, ⁴Yonsei University College of Medicine, Seoul, Korea, Republic of, ⁵Asan Medical Center, Seoul, Korea, Republic of, ⁶Samsung Medical Center, Seoul, Korea, Republic of, ⁷Seoul St Mary's Hospital, Seoul, Korea, Republic of, ⁸Keimyung University School of Medicine, Daegu, Korea, Republic of, ⁹Inje University, Busan Paik Hospital, Busan, Korea, Republic of, ¹⁰Seoul National University College of Medicine, Seoul, Korea, Republic of
*Purpose: Tacrolimus is the key drug in clinical transplant, which has narrow therapeutic index. A few studies reported the association of tacrolimus metabolism rate with…